Cited by 2,435HIV/AIDS Research and InterventionsHIV/AIDS drug development and treatmentHIV Research and Treatment

The DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index.

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.

Open access

Abdool Karim, Quarraisha, Abdool Karim, Salim S., Frohlich, Janet A., Grobler, Anneke C., Baxter, Cheryl, Mansoor, Leila E., Kharsany, Ayesha B. M., Sibeko, Sengeziwe, Mlisana, Koleka P., Omar, Zaheen, Gengiah, Tanuja N., Maarschalk, Silvia, Arulappan, Natasha, Mlotshwa, Mukelisiwe, Morris, Lynn, Taylor, Douglas, on behalf of the CAPRISA 004 Trial Group·2010·Science

DOI 10.1126/science.1193748PMC PMC3001187

Open this paper in CoChat — free account

Abstract

The Centre for the AIDS Program of Research in South Africa (CAPRISA) 004 trial assessed the effectiveness and safety of a 1% vaginal gel formulation of tenofovir, a nucleotide reverse transcriptase inhibitor, for the prevention of HIV acquisition in women. A double-blind, randomized controlled trial was conducted comparing tenofovir gel (n = 445 women) with placebo gel (n = 444 women) in sexually active, HIV-uninfected 18- to 40-year-old women in urban and rural KwaZulu-Natal, South Africa. HIV serostatus, safety, sexual behavior, and gel and condom use were assessed at monthly follow-up visits for 30 months. HIV incidence in the tenofovir gel arm was 5.6 per 100 women-years (person time of study observation) (38 out of 680.6 women-years) compared with 9.1 per 100 women-years (60 out of 660.7 women-years) in the placebo gel arm (incidence rate ratio = 0.61; P = 0.017). In high adherers (gel adherence > 80%), HIV incidence was 54% lower (P = 0.025) in the tenofovir gel arm. In intermediate adherers (gel adherence 50 to 80%) and low adherers (gel adherence < 50%), the HIV incidence reduction was 38 and 28%, respectively. Tenofovir gel reduced HIV acquisition by an estimated 39% overall, and by 54% in women with high gel adherence. No increase in the overall adverse event rates was observed. There were no changes in viral load and no tenofovir resistance in HIV seroconverters. Tenofovir gel could potentially fill an important HIV prevention gap, especially for women unable to successfully negotiate mutual monogamy or condom use.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1126/science.1193748

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (2008) · The Nephron journals/Nephron journals · doi:10.1159/000180580 · Cited by 15,291
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., Goicochea, P., Casapía, M., Guanira-Carranza, J. V., Ramirez-Cardich, M. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1011205 · Cited by 5,096
Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand
Rerks‐Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Chiu, J., Paris, R., Premsri, N., Namwat, C., de Souza, M. S., Adams, E. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0908492 · Cited by 3,036
Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial.
Auvert, B., Taljaard, D., Lagarde, E., Sobngwi-Tambekou, J., Sitta, R., & Puren, A. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020298 · Cited by 2,451
Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial.
Bailey, R. C., Moses, S., Parker, C. B., Agot, K., Maclean, I., Krieger, J. N., Williams, C. F., Campbell, R. T., & Ndinya-Achola, J. O. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60312-2 · Cited by 2,292
Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial.
Gray, R. H., Kigozi, G., Serwadda, D., Makumbi, F., Watya, S., Nalugoda, F., Kiwanuka, N., Moulton, L. H., Chaudhary, M. A., Chen, M. Z., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60313-4 · Cited by 2,226
Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial
Grosskurth, H., Todd, J., Mwijarubi, E., Mayaud, P., Nicoll, A., ka-Gina, G., Newell, J., Grosskurth, H., Todd, J., Mayaud, P., et al. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91380-7 · Cited by 1,387
Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial
Damme, L. V., Gita Ramjee, H., Alary, M., Vuylsteke, B., Chandeying, V., Rees, H., Sirivongrangson, P., Mukenge-Tshibaka, L., Ettiègne-Traoré, V., Uaheowitchai, C., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11079-8 · Cited by 796
Prevention of SIV Infection in Macaques by ( R )-9-(2-Phosphonylmethoxypropyl)adenine
Tsai, C., Follis, K. E., Sabó, A., Beck, T. W., Grant, R., Bischofberger, N., Benveniste, R. Ė., & Black, R. J. (1995) · Science · doi:10.1126/science.270.5239.1197 · Cited by 563
HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response
Karim, S. S. A., Churchyard, G., Karim, Q. A., & Lawn, S. D. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60916-8 · Cited by 544
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial
Jackson, J. B., Musoke, P., Fleming, T. R., Guay, L. A., Bagenda, D. S., Allen, M., Nakabiito, C., Sherman, J., Bakaki, P., Owor, M., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14341-3 · Cited by 523
Risk compensation: the Achilles' heel of innovations in HIV prevention?
Cassell, M. M., Halperin, D. T., Shelton, J. D., & Stanton, D. (2006) · BMJ · doi:10.1136/bmj.332.7541.605 · Cited by 390
HIV prevention: the need for methods women can use.
STEIN, Z. A. (1990) · American Journal of Public Health · doi:10.2105/ajph.80.4.460 · Cited by 379
Who infects whom? HIV-1 concordance and discordance among migrant and non-migrant couples in South Africa
Lurie, M. N., Williams, B. G., Zuma, K. K., Mkaya-Mwamburi, D., Garnett, G. P., Sweat, M. D., Gittelsohn, J., & Karim, S. S. A. (2003) · AIDS · doi:10.1097/00002030-200310170-00013 · Cited by 310
Efficacy of Postexposure Prophylaxis after Intravaginal Exposure of Pig-Tailed Macaques to a Human-Derived Retrovirus (Human Immunodeficiency Virus Type 2)
Otten, R. A., Smith, D. K., Adams, D. R., Pullium, J. K., Jackson, E., Kim, C. N., Jaffe, H. W., Janssen, R. S., Butera, S., & Folks, T. M. (2000) · Journal of Virology · doi:10.1128/jvi.74.20.9771-9775.2000 · Cited by 238
Weighing the gold in the gold standard: challenges in HIV prevention research
PADIAN, N. S., McCoy, S. I., Balkus, J. E., & Wasserheit, J. N. (2010) · AIDS · doi:10.1097/qad.0b013e328337798a · Cited by 211
Complete Protection from Repeated Vaginal Simian-Human Immunodeficiency Virus Exposures in Macaques by a Topical Gel Containing Tenofovir Alone or with Emtricitabine
Parikh, U. M., Dobard, C., Sharma, S., Cong, M.-E., Jia, H., Martin, A., Pau, C., Hanson, D. L., Guenthner, P. C., Smith, J., et al. (2009) · Journal of Virology · doi:10.1128/jvi.01073-09 · Cited by 186
In Vitro and Ex Vivo Testing of Tenofovir Shows It Is Effective As an HIV-1 Microbicide
Rohan, L. C., Moncla, B. J., Ayudhya, R. P. K. N., Cost, M. R., Huang, Y., Gai, F., Billitto, N., Lynam, J. D., Pryke, K. M., Graebing, P. W., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009310 · Cited by 183
In Vitro and in Vivo Characterization of a Potential Universal Placebo Designed for Use in Vaginal Microbicide Clinical Trials
Tien, D., Schnaare, R. L., Kang, F., Cohl, G., McCormick, T. J., Moench, T. R., Doncel, G. F., Watson, K. M., Buckheit, R. W., Lewis, M. G., et al. (2005) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2005.21.845 · Cited by 178
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women
Mayer, K. H., Maslankowski, L., Gai, F., El-Sadr, W. M., Justman, J. E., Kwiecien, A., Mâsse, B. R., Eshleman, S. H., Hendrix, C. W., Morrow, K. M., et al. (2006) · AIDS · doi:10.1097/01.aids.0000210608.70762.c3 · Cited by 173
Acyclic nucleoside phosphonates: Past, present and future
Clercq, E. D. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.09.014 · Cited by 149
Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004
Pillay, V., Ledwaba, J., HUNT, G. M., Rakgotho, M., Singh, B., Makubalo, L., Bennett, D., Puren, A. J., & Morris, L. (2008) · Antiviral Therapy · doi:10.1177/135965350801302s09 · Cited by 104
Self-citation
Acute Renal Failure Associated with Tenofovir Treatment in a Patient with Acquired Immunodeficiency Syndrome
Schaaf, B., Aries, S. P., Kramme, E., Steinhoff, J., & Dalhoff, K. (2003) · Clinical Infectious Diseases · doi:10.1086/376643 · Cited by 98
Methodological Challenges in Biomedical HIV Prevention Trials
Institute of Medicine (2008) · National Academies Press eBooks · doi:10.17226/12056 · Cited by 89
Immunopathogenesis of Hepatic Flare in HIV/Hepatitis B Virus (HBV)–Coinfected Individuals after the Initiation of HBV‐Active Antiretroviral Therapy
Crane, M., Oliver, B., Matthews, G. V., Avihingsanon, A., Ubolyam, S., Markovska, V. C., Chang, J. J., Dore, G. J., Price, P., Visvanathan, K., et al. (2009) · The Journal of Infectious Diseases · doi:10.1086/597276 · Cited by 87
The evolving HIV epidemic in South Africa
Karim, Q. A., & Karim, S. S. A. (2002) · International Journal of Epidemiology · doi:10.1093/ije/31.1.37 · Cited by 69
Uptake of provider-initiated HIV testing and counseling among women attending an urban sexually transmitted disease clinic in South Africa – missed opportunities for early diagnosis of HIV infection
Kharsany, A. B. M., Karim, Q. A., & Karim, S. S. A. (2010) · AIDS Care · doi:10.1080/09540120903254005 · Cited by 39
Self-citation
Screening for ‘window‐period’ acute HIV infection among pregnant women in rural South Africa
Kharsany, A. B. M., Hancock, N. L., Frohlich, J., Humphries, H., Karim, S. S. A., & Karim, Q. A. (2010) · HIV Medicine · doi:10.1111/j.1468-1293.2010.00838.x · Cited by 37
Self-citation
Toward an information–motivation–behavioral skills model of microbicide adherence in clinical trials
Ferrer, R. A., Morrow, K. M., Fisher, W. A., & Fisher, J. D. (2010) · AIDS Care · doi:10.1080/09540121003623719 · Cited by 31
Antiretroviral Prophylaxis for the Prevention of HIV Infection: Future Implementation Challenges
Karim, S. S. A., & Baxter, C. (2008) · HIV Therapy · doi:10.2217/17584310.3.1.3 · Cited by 29
Self-citation
The impact of microbicides on HIV and STD transmission: model projections
Watts, C. H., & Vickerman, P. T. (2001) · AIDS · doi:10.1097/00002030-200102001-00064 · Cited by 27
Microbicide Trials Network CLARIFICATION MEMO #02 TO: MTN-003 DAIDS Document ID #10622 Phase 2B Safety and Effectiveness Study of Tenofovir 1% Gel, Tenofovir Disoproxil Fumarate Tablet and Emtricitabine/Tenofovir Disoproxil Fumarate Tablet for the Prevention of HIV Infection in Women
Coumi, N., Guddera, V., & Investigator, S. (2009) · Cited by 16

Research works printed but not linked: 1

R. S. Brown D. Goodwin S. Zhang E. Fagan paper presented at the 13th International Symposium on Viral Hepatitis and Liver Disease (ISVHLD) Washington DC 20 to 24 March 2009.

Sorted by citations

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., Goicochea, P., Casapía, M., Guanira-Carranza, J. V., Ramirez-Cardich, M. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1011205 · Cited by 5,096
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Baeten, J. M., Donnell, D., Ndase, P., Mugo, N. R., Campbell, J. D., Wangisi, J., Tappero, J. W., Bukusi, E. A., Cohen, C. R., Katabira, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1108524 · Cited by 3,256
Sexually Transmitted Infections Treatment Guidelines, 2021
Workowski, K. A., Bachmann, L. H., Chan, P. A., Johnston, C. M., Muzny, C. A., Park, I., Reno, H., Zenilman, J. M., & Bolan, G. A. (2021) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr7004a1 · Cited by 3,018
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Thigpen, M. C., Kebaabetswe, P. M., Paxton, L. A., Smith, D. K., Rose, C. E., Segolodi, T. M., Henderson, F. L., Pathak, S. R., Soud, F. A., Chillag, K. L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110711 · Cited by 1,996
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Marrazzo, J. M., Ramjee, G., Richardson, B. A., Gomez, K., Mgodi, N., Nair, G., Palanee, T., Nakabiito, C., van der Straten, A., Noguchi, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1402269 · Cited by 1,296

See all 2,435

Authors: Abdool Karim, Q., Abdool Karim, S. S., Frohlich, J. A., Grobler, A. C., Baxter, C., Mansoor, L. E., Kharsany, A. B. M., Sibeko, S., Mlisana, K. P., Omar, Z., Gengiah, T. N., Maarschalk, S., Arulappan, N., Mlotshwa, M., Morris, L., Taylor, D., & on behalf of the CAPRISA 004 Trial Group
Affiliations: Centre for the AIDS Program of Research in South Africa (CAPRISA), Durban 4013, South Africa.
Centre for the AIDS Programme of Research in South Africa (ZA)
National Institute for Communicable Diseases (ZA)
Family Health International 360 (US)
ORCID: Grobler, Anneke C.
Baxter, Cheryl
Mansoor, Leila E.
Kharsany, Ayesha B. M.
Sibeko, Sengeziwe
Mlisana, Koleka P.
Gengiah, Tanuja N.
Arulappan, Natasha
Morris, Lynn
Taylor, Douglas
Venue: Science
Publisher: American Association for the Advancement of Science (AAAS)
Published: 2010-09-03
Volume: 329
Issue: 5996
Pages: 1168-1174
ISSN: 0036-8075 (ISSN-L)
1095-9203
DOI: 10.1126/science.1193748
PMC: PMC3001187
OpenAlex: W2146634980
Cited by: 2,435
References: 33
Citations by year: 2026: 13 · 2025: 27 · 2024: 29 · 2023: 27 · 2022: 43 · 2021: 81 · 2020: 65 · 2019: 81 · 2018: 106 · 2017: 150 · 2016: 182 · 2015: 212 · 2014: 292 · 2013: 328 · 2012: 385
FWCI: 229.92
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Science (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Figshare (submittedVersion, cc-by)
ResearchSpace (University of KwaZulu-Natal) (submittedVersion)
Columbia Academic Commons (Columbia University)
Funders: National Institute of Allergy and Infectious Diseases (U01AI046749, U01AI068633, U19AI051794, U01AI068619, AI 51794)
Fogarty International Center (D43TW000231)
Topics: Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
Keywords: tenofovir gel, HIV prevention, microbicides, vaginal gel, women, HIV incidence, antiretroviral drugs, nucleotide reverse transcriptase inhibitors, HIV seroconversion, tenofovir resistance, sexual behavior, condom use
MeSH terms: Tenofovir, Adenine, Administration, Intravaginal, Adolescent, Adult, Anti-Infective Agents, Local, Double-Blind Method, Female, Humans, Patient Compliance, Pregnancy, Pregnancy Outcome, Rural Population, Sexual Behavior, South Africa, Urban Population, Vaginal Creams, Foams, and Jellies, HIV-1, HIV Infections, Incidence, Anti-HIV Agents, Viral Load, Drug Resistance, Viral, Young Adult, Organophosphonates

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks